Evolving metformin treatment strategies in Type-2 diabetes: From immediate-release metformin monotherapy to extended-release combination therapy

American Journal of Therapeutics

Volumn 21, Issue 3, 2014, Pages 198-210

  Chacra, Antonio R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

extended release; immediate release; metformin; treatment; type 2 diabetes

Indexed keywords

ACARBOSE; BUFORMIN; CHLORPROPAMIDE; CLOMIFENE; CYANOCOBALAMIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMIN PLUS SAXAGLIPTIN; ORAL ANTIDIABETIC AGENT; PHENFORMIN; SAXAGLIPTIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION;

ABDOMINAL DISCOMFORT; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED RELEASE FORMULATION; CREATININE CLEARANCE; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EXTENDED RELEASE FORMULATION; FATTY ACID OXIDATION; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; HYPOGLYCEMIA; IMMEDIATE RELEASE FORMULATION; INDIGESTION; INSULIN TREATMENT; LACTIC ACIDOSIS; LIPOGENESIS; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MICROANGIOPATHY; MONOTHERAPY; NAUSEA AND VOMITING; NEWBORN JAUNDICE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OFF LABEL DRUG USE; OVARY POLYCYSTIC DISEASE; PREMATURITY; PRIORITY JOURNAL; RISK REDUCTION; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE AGGREGATION; THROMBOSIS; WEIGHT GAIN; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG DESIGN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DRUG DESIGN; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PRACTICE GUIDELINES AS TOPIC;

EID: 84900831504     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318235f1bb     Document Type: Article

References (83)

1. Witters LA. The blooming of the French lilac. J Clin Invest. 2001;108:1105-1107.
2. Campbell IW. Metformin-life begins at 50: a symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 2007. Br J Diab Vasc Dis. 2007;7:247-252.
3. US FDA press release: FDA approves new diabetes drug. 30 December 1994. Available at: http://classic-web. archive.org/web/20070929152824/http://www.fda. gov/bbs/topics/ANSWERS/ANS00627.html. Accessed June 20, 2011.
4. SDI/Verispan, VONA. 2009 Top 200 generic drugs by total prescriptions. Drug Topics, 2010. Available at: http://drugtopics.modernmedicine.com/ drugtopics/data/articlestandard//drugtopics/252010/674982/article.pdf. Accessed August 7, 2011.
5. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972. [Erratum in: Diabetes Care, 2006].
6. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23:579-593.
7. Latin American Diabetes Association (ALAD). Guidelines for the diagnosis, control and treatment of type 2 diabetes mellitus. Rev Assoc Lat Diab. 2000;8:101-167.
8. US FDA. Glucophage prescribing Information for the US, 2008. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/020357s031, 021202s016lbl. pdf. Accessed June 20, 2011.
9. Lerario AC, Chacra AR, Pimazoni-Netto A, et al. Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society. Diabetol Metab Syndr. 2010;2:35.
10. Zhou G, Myers R, Li Y, et al. Role of AMP-Activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167-1174.
11. Kim YD, Park KG, Lee YS, et al. Metformin inhibits hepatic gluconeogenesis through AMP-Activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes. 2008;57:306-314.
12. Collier CA, Bruce CR, Smith AC, et al. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am J Physiol Endocrinol Metab. 2006;291:E182-E189.
13. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997; 103:491-497.
14. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541-549.
15. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-865 [Erratum in: Lancet. 1998;352:1558].
16. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
17. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147: 386-399.
18. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137:25-33.
19. Roussel R, Travert F, Pasquet B, et al; for the Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170:1892-1899.
20. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
21. Knowler WC, Fowler SE, Hamman RF, et al; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374: 1677-1686.
22. Rowan JA, Hague WM, Gao W, et al; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358:2003-2015 [Erratum in: N Engl J Med. 2008;359:106].
23. Balani J, Hyer SL, Rodin DA, et al. Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study. Diabet Med. 2009;26:798-802.
24. Palomba S, Pasquali R, Orio F Jr, et al. Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-To-head randomized controlled studies and meta-Analysis. Clin Endocrinol (Oxf). 2009;70:311-321.
25. Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiroinositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. January 20, 2010:CD003053.
26. Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137: 482-488.
27. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304-1305.
28. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620-1625.
29. Levri KM, Slaymaker E, Last A, et al. Metformin as treatment for overweight and obese adults: a systematic review. Ann Fam Med. 2005;3:457-461.
30. Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother. 2008;42:817-826.
31. Brown JB, Pedula K, Barzilay J, et al. Lactic acidosis rates in type 2 diabetes. Diabetes Care. 1998;21:1659-1663 [Erratum in: Diabetes Care 1998;21:2203].
32. Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-Associated lactic acidosis'. Diabetes Obes Metab. 2001;3:195-201.
33. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998;338:265-266.
34. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;4: CD002967.
35. Herrington WG, Levy JB. Metformin: effective and safe in renal disease? Int Urol Nephrol. 2008;40:411-417.
36. Sambol NC, Chiang J, Lin ET, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35:1094-1102.
37. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-To-moderate renal insufficiency. Diabetes Care. 2011;34:1431-1437.
38. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf. 1999;20: 489-503.
39. Haupt E, Knick B, Koschinsky T, et al. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab. 1991;17:224-231.
40. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs. 1995; 49:721-749.
41. Florez H, Luo J, Castillo-Florez S, et al. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med. 2010;122:112-120.
42. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
43. Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004; 27:2800-2805.
44. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002;25: 1015-1021.
45. Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25: 2958-2971.
46. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27: 2149-2153.
47. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281: 2005-2012.
48. Nichols GA, Alexander CM, Girman CJ, et al. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care. 2006;29:504-509.
49. Hermann LS. Biguanides and sulphonylureas as combination therapy in NIDDM. Diabetes Care. 1990;13:37-41.
50. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3853-3860.
51. Vilsbll T, Knop FK. DPP IV inhibitors-current evidence and future directions. Br J Diabetes Vasc Dis. 2007;7:69-74.
52. Chacra AR, Tan GH, Apanovitch A, et al; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial. Int J Clin Practice. 2009;63:1395-1406.
53. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001; 24:489-494.
54. Migoya EM, Miller J, Larson P, et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations. Diabetes. 2007;56(suppl 1):A74.
55. Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26:540-549.
56. Sharma MD. Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. Ther Clin Risk Manag. 2010;6:233-237.
57. Jadzinsky M, Pfu tzner A, Paz-Pacheco E, et al; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611-622.
58. DeFronzo RA, Hissa MN, Garber AJ, et al; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649-1655.
59. Schwartz SL, Gordi T, Hou E, et al. Clinical development of metformin extended-release tablets for type 2 diabetes: an overview. Expert Opin DrugMetab Toxicol. 2008;4:1235-1243.
60. Timmins P, Donahue S, Meeker J, et al. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet. 2005;44:721-729.
61. Cullen E, Liao J, Lukacsko P, et al. Pharmacokinetics and dose proportionality of extended-release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers. Biopharm Drug Dispos. 2004;25:261-263.
62. Gusler G, Gorsline J, Levy G, et al. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol. 2001;41:655-661.
63. Marathe P, Turner K. Steady-state pharmacokinetics of the metformin extended-release tablet versus immediate release metformin in healthy subjects. Diabetes. 2002; 51(suppl. 2):A474.
64. Wagstaff AJ, Figgitt DP. Extended-release metformin hydrochloride. Single-composition osmotic tablet formulation. Treat Endocrinol. 2004;3:327-332.
65. Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010; 49:573-588.
66. Schwartz S, Fonseca V, Berner B, et al. Efficacy, tolerability, and safety of a novel once-daily extendedrelease metformin in patients with type 2 diabetes. Diabetes Care. 2006;29:759-764.
67. Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2010;2:16.
68. Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab. 2005;7: 28-39.
69. Blonde L, Dailey GE, Jabbour SA, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20: 565-572.
70. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27: 1218-1224.
71. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20: 1512-1517.
72. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30:3017-3022.
73. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95: 68-71.
74. Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. 2005;7:722-728.
75. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24: 460-467.
76. Guillausseau PJ. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab. 2003;29:79-81.
77. Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11:338-342.
78. Stenlo f K, Raz I, Neutel J, et al. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin. 2010;26:2355-2363.
79. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23:611-614.
80. Ramsdell JW, Braunstein SN, Stephens JM, et al. Economic model of first-line drug strategies to achieve recommended glycemic control in newly diagnosed type 2 diabetes mellitus. Pharmacoeconomics. 2003;21:819-837.
81. Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med. 2011;123:15-23.
82. Rodenhuis N, De Smet PA, Barends DM. The rationale of scored tablets as dosage form. Eur J Pharm Sci. 2004;21: 305-308.
83. Wening K, Breitkreutz J. Oral drug delivery in personalized medicine: unmet needs and novel approaches. Int J Pharm. 2011;404:1-9